The White House’s commitment to push through rescheduling has been challenged by a Democratic Senator, who has demanded answers on the administration’s radio silence.
The US Drug Enforcement Agency (DEA) has placed six ‘synthetic cannabinoids’ into a temporary Schedule 1 in an effort to ‘avoid imminent hazard to public safety’.
Bright Green, one of the few companies eligible for authorisation to grow, manufacture and sell cannabis under both Federal and state laws, this week reported its Q3 figures.
An amendment to Bill H.R 5893 has been filed that aims to prevent the Federal rescheduling of cannabis.
